EMCC European Monitoring Centre on Change

Leo Pharma

Leo Pharma

Geographic Location

Country: Denmark
Region: Københavns amt
Location of affected unit(s): Ballerup


Sector: Manufacturing
Manufacture of pharmaceuticals, medicinal chemical and botanical products
21.20 - Manufacture of pharmaceutical preparations
Number Employed: 1705

Employment Effects

Announcement Date: 12-01-2023
Planned Job Reductions min: 300
Type of Restructuring: Internal restructuring
Employment Effect Start: 12-01-2023
Direct Dismissals: 300

Additional Information

Leo Pharma, a multinational Danish manufacturer of pharmaceuticals, has announced the company will cut 300 jobs from it's Danish workforce. The restructuring is a result of the closure of their Ballerup research department which had 300 workers, including researchers, support and distribution staff. The closure of the research department is part of the company's new strategy, outsourcing innovation and research externally. Further, the future strategy for the company is to manufacture pharmaceuticals on license from other biotek companies. 

Leo Pharma has a presence in more than 100 countries and employs around 1700 people in Denmark.

A previous restructuring event was recorded in the ERM Events database for Leo Pharma. In 2022, the company announced a global restructuring which will impact 1000 employees from 2022-2024 (Leo Pharma-2022-WO).